evaluation of cellular immunity ( t-cell subsets , in vitro interleukin-2 production and interleukin-2 receptor expression , t-cell responses to mitogens and antigens , and delayed-hypersensitivity skin tests ) as well as clinical and toxicity monitoring was performed prior to treatment , at 2-week intervals during treatment , and after the cessation of treatment .
C0020966
cellular immunity
C0003320
antigens